表紙
市場調查報告書

癌胚胎抗原相關細胞黏合分子5:開發中產品分析

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 408078
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
癌胚胎抗原相關細胞黏合分子5:開發中產品分析 Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 60 Pages
簡介

本報告提供以癌胚胎抗原相關細胞黏合分子5為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您包含最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

癌胚胎抗原相關細胞黏合分子5 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Akshaya Bio Inc.
  • Celgene Corporation
  • Etubics Corporation
  • OSE Immunotherapeutics
  • Vaxon Biotech

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1976TDB

Summary:

According to the recently published report 'Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019'; Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e is a human gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. It promotes tumor development through its role as a cell adhesion molecule. It regulates differentiation, apoptosis, and cell polarity.

The report 'Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019' outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Adenocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Peritoneal Tumor and Recurrent Glioblastoma Multiforme (GBM).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
  • The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Overview
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc
    • Bavarian Nordic A/S
    • Etubics Corp
    • NantCell Inc
    • OSE Immunotherapeutics
    • Shanghai Haikang Pharmaceutical Co Ltd
    • Vaxon Biotech
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles
    • CV-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETBX-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GI-6207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Virus to Target CD66e for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-2101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CEA for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CEA for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Products
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued Products
  • Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 11, 2019: OSE Immunotherapeutics presented poster on Tedopi at SITC 2019
      • Oct 21, 2019: Bavarian Nordic reports Phase II bladder cancer trial data
      • Jun 20, 2019: Continuation of Atalante 1 phase 3 clinical rial of Tedopi in NSCLC patients post checkpoint inhibitor failure following IDMC recommendation
      • Jun 11, 2019: OSE Immunotherapeutics receives U.S. patent notice of allowance for use of Tedopi to treat brain metastasis
      • May 22, 2019: OSE Immunotherapeutics to host key opinion leader meeting on novel treatments in non-small cell lung cancer
      • Apr 02, 2019: OSE Immunotherapeutics Presented new clinical data on Tedopi (OSE2101) at AACR 2019
      • Feb 28, 2019: OSE Immunotherapeutics to present new clinical data on its immuno-oncology portfolio Tedopi at AACR 2019
      • Jan 15, 2019: OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi to treat brain metastasis
      • Nov 21, 2018: OSE receives approval for Phase II trial of tedopi and opdivo
      • Nov 02, 2018: Bavarian Nordic announces initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers
      • Oct 10, 2018: Ose Immunotherapeutics and oncology physician network Gercor announce submission of investigational new drug application to evaluate Tedopi in combination with Nivolumab in pancreatic cancer
      • Sep 20, 2018: Bavarian doses first patient in CV301 and atezolizumab Phase ll trial
      • Aug 10, 2018: HCRN study explores investigational vaccine therapy for metastatic colorectal cancer
      • Jul 11, 2018: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
      • Jul 05, 2018: OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Akshaya Bio Inc, H2 2019
  • Pipeline by Bavarian Nordic A/S, H2 2019
  • Pipeline by Etubics Corp, H2 2019
  • Pipeline by NantCell Inc, H2 2019
  • Pipeline by OSE Immunotherapeutics, H2 2019
  • Pipeline by Shanghai Haikang Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Vaxon Biotech, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top